The phosphorylating reagent bis[S-(4,4'-dimethoxytrityl)-2-mercaptoethyl]-N,N-diisopropylphosphoramidite is prepared in three steps from commercial methyl thioglycolate and diisopropylphosphoramidous dichloride. The phosphorylating reagent has been used successfully in the solid-phase synthesis of deoxyribonucleoside 5'-/3'-phosphate or -thiophosphate monoesters and oligonucleotide 5'-phosphate/-thiophosphate monoesters. Bis[S-(4,4'-dimethoxytrityl)-2-mercaptoethyl]-N,N-diisopropylphosphoramidite has also been employed in the construction of a thermolytic dinucleotide prodrug model to evaluate the ability of the reagent to produce thermosentive oligonucleotide prodrugs under mild temperature conditions ( approximately 25 degrees C) for potential therapeutic applications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/0471142700.nc1306s26 | DOI Listing |
Alzheimers Dement
December 2024
Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Background: To date, limited data exist concerning the utility of FDG-PET in detecting Alzheimer's Disease (AD) in Down Syndrome (DS). Yet, sensitive biomarkers for neurodegeneration are essential in this population genetically predisposed for AD. Therefore, we aimed at characterizing the effect of age, disease stage and AD pathology on brain metabolism in a large cohort of adults with DS.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, Montréal, QC, Canada.
Background: Biomarkers promise to significantly improve the differential diagnosis of Alzheimer's disease (AD). Plasma biomarkers, such as phosphorylated tau (p-tau), have shown potential in diagnosing AD with high accuracy. Unlike the widely-used [18 F]FDG-PET diagnostic biomarker in clinical practice, plasma p-tau is specific to AD and can provide an affordable and scalable diagnostic tool.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Background: The G protein-coupled receptor GPR39 is heavily associated with the pathogenesis of neurologic disorders, including Alzheimer's disease (AD) and related dementia (ADRD). Its dysregulation of zinc 2+ (Zn) processes triggers metallic dyshomeostasis, oxidative stress, neuroinflammation, microtubule destabilization, synaptic dysfunction, and tau phosphorylation-all hallmarks of neurodegeneration. Hence, pharmacologic modulation of GPR39 could offer an effective treatment against AD and ADRD.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.
Background: Purinergic signaling is vital in various cellular processes like neuroinflammation, synaptic transmission, Aβ clearance, and tau phosphorylation regulation. This study aims to examine if SNPs in purinergic signaling genes are associated to A/T(N) status biomarkers in Alzheimer's Disease through Genome Wide Association Studies.
Method: The SNPRelate package was used to analyze SNPs in genes related to purinergic signaling and A/T(N) markers.
Alzheimers Dement
December 2024
Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Background: The G protein-coupled receptor GPR39 is heavily associated with the pathogenesis of neurologic disorders, including Alzheimer's disease (AD) and related dementia (ADRD). Its dysregulation of zinc 2+ (Zn2+) processes triggers metallic dyshomeostasis, oxidative stress, neuroinflammation, microtubule destabilization, synaptic dysfunction, and tau phosphorylation-all hallmarks of neurodegeneration. Hence, pharmacologic modulation of GPR39 could offer an effective treatment against AD and ADRD.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!